Literature DB >> 25954015

A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.

Paul E R Ellery1, Susan A Maroney1, Brian C Cooley2, James P Luyendyk3, Mark Zogg1, Hartmut Weiler4, Alan E Mast5.   

Abstract

Tissue factor pathway inhibitor (TFPI) is a critical anticoagulant protein present in endothelium and platelets. Mice lacking TFPI (Tfpi(-/-)) die in utero from disseminated intravascular coagulation. They are rescued by concomitant tissue factor (TF) deficiency, demonstrating that TFPI modulates TF function in vivo. Recent studies have found TFPI inhibits prothrombinase activity during the initiation of coagulation and limits platelet accumulation during thrombus formation, implicating TFPI in modulating platelet procoagulant activity. To examine whether altered platelet function would compensate for the lack of TFPI and rescue TFPI-null embryonic lethality, Tfpi(+/-) mice lacking the platelet thrombin receptor, protease activated receptor 4 (PAR4; Par4(-/-)), or its coreceptor, PAR3, were mated. PAR3 deficiency did not rescue Tfpi(-/-) embryos, but >40% of expected Tfpi(-/-):Par4(-/-) offspring survived to adulthood. Adult Tfpi(-/-):Par4(-/-) mice did not exhibit overt thrombosis. However, they had focal sterile inflammation with fibrin(ogen) deposition in the liver and elevated plasma thrombin-antithrombin complexes, indicating activation of coagulation at baseline. Tfpi(-/-):Par4(-/-) mice have platelet and fibrin accumulation similar to Par4(-/-) mice following venous electrolytic injury but were more susceptible than Par4(-/-) mice to TF-induced pulmonary embolism. In addition, ∼30% of the Tfpi(-/-):Par4(-/-) mice were born with short tails. Tfpi(-/-):Par4(-/-) mice are the first adult mice described that lack TFPI with unaltered TF. They demonstrate that TFPI physiologically modulates thrombin-dependent platelet activation in a manner that is required for successful embryonic development and identify a role for TFPI in dampening intravascular procoagulant stimuli that lead to thrombin generation, even in the absence of thrombin-mediated platelet activation.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25954015      PMCID: PMC4481595          DOI: 10.1182/blood-2015-03-633958

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.

Authors:  E Camerer; W Huang; S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.

Authors:  M S Bajaj; M N Kuppuswamy; H Saito; S G Spitzer; S P Bajaj
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  Protection against thrombosis in mice lacking PAR3.

Authors:  Ethan J Weiss; Justin R Hamilton; Katy E Lease; Shaun R Coughlin
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

4.  PAR3 is a cofactor for PAR4 activation by thrombin.

Authors:  M Nakanishi-Matsui; Y W Zheng; D J Sulciner; E J Weiss; M J Ludeman; S R Coughlin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

5.  Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells.

Authors:  Hiroshi Kataoka; Justin R Hamilton; David D McKemy; Eric Camerer; Yao-Wu Zheng; Abby Cheng; Courtney Griffin; Shaun R Coughlin
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

6.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.

Authors:  T J Girard; L A Warren; W F Novotny; K M Likert; S G Brown; J P Miletich; G J Broze
Journal:  Nature       Date:  1989-04-06       Impact factor: 49.962

7.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.

Authors:  G J Broze; L A Warren; W F Novotny; D A Higuchi; J J Girard; J P Miletich
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

8.  Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.

Authors:  W F Novotny; T J Girard; J P Miletich; G J Broze
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

9.  Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets.

Authors:  J R Hamilton; I Cornelissen; S R Coughlin
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824

10.  Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.

Authors:  P Chowdary; S Lethagen; U Friedrich; B Brand; C Hay; F Abdul Karim; R Klamroth; P Knoebl; M Laffan; J Mahlangu; W Miesbach; J Dalsgaard Nielsen; M Martín-Salces; P Angchaisuksiri
Journal:  J Thromb Haemost       Date:  2015-04-06       Impact factor: 5.824

View more
  12 in total

Review 1.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

2.  A combined deficiency of tissue factor and PAR-4 is associated with fatal pulmonary hemorrhage in mice.

Authors:  Michael F Bode; Nigel Mackman
Journal:  Thromb Res       Date:  2016-08-22       Impact factor: 3.944

3.  Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.

Authors:  Sravya Kattula; Yaqiu Sang; Gustaaf de Ridder; Anna C Silver; Emma G Bouck; Brian C Cooley; Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2021-09-06       Impact factor: 5.824

4.  Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

Authors:  Michelle M Castillo; Qiuhui Yang; Min Zhan; Amy Y Pan; Michael W Lawlor; Alan E Mast; Rashmi Sood
Journal:  Blood Adv       Date:  2019-02-12

5.  Generation of α-1,3-galactosyltransferase knocked-out transgenic cloned pigs with knocked-in five human genes.

Authors:  Dae-Jin Kwon; Dong-Hwan Kim; In-Sul Hwang; Dong-Ern Kim; Hyung-Joo Kim; Jang-Seong Kim; Kichoon Lee; Gi-Sun Im; Jeong-Woong Lee; Seongsoo Hwang
Journal:  Transgenic Res       Date:  2016-08-23       Impact factor: 2.788

6.  Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.

Authors:  Stella Thomassen; Tom G Mastenbroek; Frauke Swieringa; Kristien Winckers; Marion A H Feijge; Roy Schrijver; Judith M E M Cosemans; Susan A Maroney; Alan E Mast; Tilman M Hackeng; Johan W M Heemskerk
Journal:  Thromb Haemost       Date:  2018-02-16       Impact factor: 5.249

Review 7.  Targeting TFPI for hemophilia treatment.

Authors:  Julie A Peterson; Susan A Maroney; Alan E Mast
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

8.  The contribution of TFPIα to the hemostatic response to injury in mice.

Authors:  Tanya T Marar; Nicholas D Martinez; Susan A Maroney; Amy E Siebert; Jie Wu; Timothy J Stalker; Maurizio Tomaiuolo; Sinny Delacroix; Robert D Simari; Alan E Mast; Lawrence F Brass
Journal:  J Thromb Haemost       Date:  2021-07-14       Impact factor: 16.036

9.  Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression.

Authors:  Amy E Siebert; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  J Thromb Haemost       Date:  2021-04-12       Impact factor: 16.036

10.  Tissue factor pathway inhibitor is required for cerebrovascular development in mice.

Authors:  Susan A Maroney; Randal J Westrick; Audrey C Cleuren; Nicholas D Martinez; Amy E Siebert; Mark Zogg; David Ginsburg; Hartmut Weiler; Alan E Mast
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.